New Investigational Drug for HSV

New CEO of Squarex, Jack V. Talley discusses the positive results of the phase 2 study on their new investigational drug candidate SQX770, a topical immunomodulator treatment to extend the time between herpes labialis (recurrent cold sores) outbreaks caused by Herpes Simplex Virus 1 or Herpes Simplex Virus 2.  Squarex is a clinical-stage pharmaceutical company.

Read More

Kleo Pharmaceuticals – Immuno-Oncology Drugs

Kleo Pharmaceuticals is a unique immuno-oncology company poised to solve some of the problems dominating the headlines for the biopharmaceutical industry. CEO Dr. Doug Manion discusses the development of next-generation bispecific compounds designed to emulate or enhance the activity of biologics, which directly engage patients’ immune systems to target and destroy cancer cells. Human studies are anticipated in 2020.

Read More

Study of Hip Fracture Care for Older Patients

Dr. Rebecca Craik, dean of the College of Health Sciences at Arcadia University discusses a study recently published in JAMA (Sept 2019) in which she was co-PI, that looked at the effects of home-based physical therapy on elderly hip fracture patients.  The study shows that more rigorous physical therapy than what is usually offered can help return the patient to their “before” lifestyle.

Read More

Spinal cord regeneration technology

Dr. Jerry Silver, Professor of Neurosciences at Case Western Reserve University’s School of Medicine and advisor to NervGen Pharma, discusses NervGen Pharma’s spinal cord regeneration technology. In animal studies an injectable peptide, developed by Dr. Silver and NervGen, allowed paralyzed rats to walk again. Phase 1 clinical trials are on the horizon in 2020.

Read More